GZMB

Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer

Retrieved on: 
Tuesday, August 8, 2023
Lymphoma, TST, CD25, Nature Cancer, Pharmaceutical innovations, Food and Drug Administration, Cancer, Immunity, Toxicity, Antibody, HKEX, Patient, Interleukin 2, GZMB, Ophthalmology, Immune system, Neoplasm, Cytokine, PD-1, IL2, TeST TST-13 Junior, Food, Safety, Vaccine, Pharmaceutical industry, Palladium, Regulatory T cell

and SUZHOU, China, Aug. 7, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announced that the preclinical results of IBI363 were published in Nature Cancer (IF=22.7).

Key Points: 
  • and SUZHOU, China, Aug. 7, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announced that the preclinical results of IBI363 were published in Nature Cancer (IF=22.7).
  • Interleukin 2 (Interleukin-2, IL-2) is the first cytokine to be discovered and identified as playing a pivotal role in T-cell growth and expansion.
  • In contrast, "not-α" IL-2 is prone to expand CD25 negative bystander T cells, and this limits its anti-tumor efficacy.
  • The corresponding author, Dr. Kaijie He of Innovent Biologics stated, "We are very pleased that the results of this study are published and highlighted in the current issue of Nature Cancer.

CytoSite Bio Presents First-in-Human Data at Radiological Society of North American Annual Meeting

Retrieved on: 
Monday, November 28, 2022
Oncology, Health, Clinical Trials, Research, Radiology, Science, Doctor of Philosophy, Massachusetts General Hospital, Immune system, PET, Hematology-Oncology and Stem Cell Transplantation Research Center, Drug combination, NSCLC, Hospital, GZMB, RSNA, Large-cell lung carcinoma, Physician, Melanoma, Patient, ICI, Hematology, Neoplasm, Oncology, Pembrolizumab, Radiological Society of North America, Annual general meeting, MD, NK, Cancer, Granzyme, Immunotherapy, Associate, Safety, Principal, Medical imaging

CytoSite Bio , a company developing precision imaging products that determine patient response to immuno-oncology therapy today shared new data at the Radiological Society of North American (RSNA) Annual Meeting in Chicago, IL.

Key Points: 
  • CytoSite Bio , a company developing precision imaging products that determine patient response to immuno-oncology therapy today shared new data at the Radiological Society of North American (RSNA) Annual Meeting in Chicago, IL.
  • These data come from a Phase I trial assessing the safety and feasibility of GzmB PET imaging in subjects with melanoma and non-small cell lung cancer (NSCLC) receiving KEYTRUDA (pembrolizumab).
  • I am pleased that these early, promising data are showing how that option could become a reality.
  • CytoSite Bio is developing precision imaging products that determine patient response to immuno-oncology therapy very early in the treatment cycle.

AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer

Retrieved on: 
Monday, April 11, 2022
UPMC, Private Securities Litigation Reform Act, Company, Cancer, FOXP3, PSLRA, Celecoxib, Therapy, The I.V. Stalin White Sea – Baltic Sea Canal, CCL5, NYSE, Triple-negative breast cancer, CXCL10, Survival, AACR, Doctor of Philosophy, Research, American Association, Metastasis, Neoplasm, GZMB, American, Ovarian cancer, AIM ImmunoTech, Immunology, Association, American Association for Cancer Research, COVID-19, CTL, GLOBE, Degenerative disease, CKM, AIM, Lists of diseases, Breast cancer, CCL22, CXCL12, Patient, Disease, Pembrolizumab, Medical imaging, Pharmaceutical industry, Medical device, Vaccine, Dietary supplement, Regulatory T cell, Roswell Park Comprehensive Cancer Center, TME, Rintatolimod, MD

OCALA, Fla., April 11, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the presentation of positive data from a Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate, Ampligen® (also known as rintatolimod), interferonα-2b, and pembrolizumab at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held April 8-13, 2022, in New Orleans, Louisiana.

Key Points: 
  • In the study, six evaluable patients (33-75 years) with mTNBC received 6 doses of Ampligen (200 mg i.v.
  • Three patients had stable disease lasting 2.4, 2.5 and 3.8 months, as of data cut off September 1, 2021.
  • An additional patient (non-evaluable) had a partial response (breast tumor autoamputation) with massive tumor necrosis in the post-CKM biopsy.
  • Significant additional testing and trials will be required to determine whether Ampligen will be an effective treatment of Stage 4 metastatic triple negative breast cancer or otherwise, and no assurance can be given that this will be the case.